SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

BRIEF-Celldex Reports Results From Phase 2 Study Of Barzolvolimab In Atopic Dermatitis

BRIEF-Celldex Reports Results From Phase 2 Study Of Barzolvolimab In Atopic Dermatitis Nov 19 (Reute

CLDX

Related stories